Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

NCT03509012 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Squamous Cell of Head and Neck
Carcinoma, Non-Small-Cell Lung
Small Cell Lung Carcinoma

Interventions

DRUG: Durvalumab
DRUG: Tremelimumab
DRUG: Cisplatin (dose level 4)
DRUG: Cisplatin (dose level 3)
DRUG: Carboplatin (dose level 1)
DRUG: Carboplatin (dose level 2)
DRUG: Etoposide (dose level 1)
DRUG: Etoposide (dose level 2)
DRUG: Paclitaxel
DRUG: Pemetrexed
RADIATION: External beam radiation (dose level 1)
RADIATION: External beam radiation (dose level 2)
RADIATION: External beam radiation (hyperfractionated)
DRUG: Cisplatin (dose level 1)
DRUG: Cisplatin (dose level 2)
RADIATION: External beam radiation (standard)

Sponsor

AstraZeneca